Polypharmacy in multiple sclerosis: Relationship with fatigue, perceived cognition, and objective cognitive performance

Journal of Psychosomatic Research

Volumn 76, Issue 5, 2014, Pages 400-404

  Thelen, Joanie M ^a   Lynch, Sharon G ^b   Bruce, Amanda S ^a   Hancock, Laura M ^c   Bruce, Jared M ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c BROWN UNIVERSITY   (United States)

Author keywords

Cognition; Fatigue; Multiple sclerosis; Objective impairment; Polypharmacy; Subjective impairment

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIHYPERTENSIVE AGENT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; HORMONE; SPASMOLYTIC AGENT;

ADULT; AMNESIA; APTITUDE TEST; ARTICLE; AUDITORY VERBAL LEARNING TEST; BECK DEPRESSION INVENTORY; COGNITIVE DEFECT; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DISEASE CONTROL; DISEASE DURATION; DISSOCIATIVE EXPERIENCES SCALE; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FATIGUE IMPACT SCALE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY FOR INTENTIONS SCREENING TEST; MIDDLE AGED; MULTIPLE SCLEROSIS; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; PHYSICAL DISABILITY; POLYPHARMACY; PROCESSING SPEED DIFFICULTIES SCALE; PROSPECTIVE AND RETROSPECTIVE MEMORY QUESTIONNAIRE; PROSPECTIVE MEMORY; SELF REPORT; STROOP TEST; SYMBOL DIGIT MODALITIES TEST;

COGNITION; FATIGUE; MULTIPLE SCLEROSIS; OBJECTIVE IMPAIRMENT; POLYPHARMACY; SUBJECTIVE IMPAIRMENT;

ADULT; COGNITION; COGNITION DISORDERS; FATIGUE; FEMALE; HUMANS; MALE; MEMORY; MEMORY DISORDERS; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROPSYCHOLOGICAL TESTS; POLYPHARMACY; QUESTIONNAIRES;

EID: 84899068240     PISSN: 00223999     EISSN: 18791360     Source Type: Journal    
DOI: 10.1016/j.jpsychores.2014.02.013     Document Type: Article

References (47)

1. Crayton HJ, Rossman HS Managing the symptoms of multiple sclerosis: a multimodal approach. Clin Ther Apr 2006, 28:445-460. [Review].
2. Krupp LB, Alvarez LA, LaRocca NG, Scheinberg LC Fatigue in multiple sclerosis. Arch Neurol Apr 1988, 45:435-437. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
3. Peyser JM, Edwards KR, Poser CM, Filskov SB Cognitive function in patients with multiple sclerosis. Arch Neurol Sep 1980, 37:577-579.
4. Rao SM, Leo GJ, Ellington L, Nauertz T, Bernardin L, Unverzagt F Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology May 1991, 41:692-696. [Research Support, U.S. Gov't, P.H.S.].
5. Astrand E, Astrand B, Antonov K, Petersson G Potential drug interactions during a three-decade study period: a cross-sectional study of a prescription register. Eur J Clin Pharmacol Sep 2007, 63:851-859.
6. Jyrkka J, Enlund H, Lavikainen P, Sulkava R, Hartikainen S Association of polypharmacy with nutritional status, functional ability and cognitive capacity over a three-year period in an elderly population. Pharmacoepidemiol Drug Saf May 2011, 20:514-522. [Research Support, Non-U.S. Gov't].
7. Jyrkka J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S Polypharmacy status as an indicator of mortality in an elderly population. Drugs Aging 2009, 26:1039-1048. [Comparative Study Research Support, Non-U.S. Gov't].
8. Hartikainen S, Lonnroos E Systematic review: use of sedatives and hypnotics, antidepressants and benzodiazepines in older people significantly increases their risk of falls. Evid Based Med Apr 2010, 15:59. [Comment].
9. Bruce JM, Hancock LM, Lynch SG Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report. Mult Scler Jan 2010, 16:112-120.
10. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol Dec 2005, 58:840-846.
11. Kurtzke JF Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology Nov 1983, 33:1444-1452.
12. Fulton MM, Allen ER Polypharmacy in the elderly: a literature review. J Am Acad Nurse Pract Apr 2005, 17:123-132.
13. Gnjidic D, Hilmer SN, Blyth FM, Naganathan V, Waite L, Seibel MJ, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes. J Clin Epidemiol Sep 2012, 65:989-995.
14. Haider SI, Johnell K, Thorslund M, Fastbom J Analysis of the association between polypharmacy and socioeconomic position among elderly aged > or =77years in Sweden. Clin Ther Feb 2008, 30:419-427. [Research Support, Non-U.S. Gov't].
15. Linjakumpu T, Hartikainen S, Klaukka T, Veijola J, Kivela SL, Isoaho R Use of medications and polypharmacy are increasing among the elderly. J Clin Epidemiol Aug 2002, 55:809-817.
16. Onder G, Liperoti R, Fialova D, Topinkova E, Tosato M, Danese P, et al. Polypharmacy in nursing home in Europe: results from the SHELTER study. J Gerontol A Biol Sci Med Sci Jun 2012, 67:698-704. [Research Support, Non-U.S. Gov't].
17. Richardson K, Ananou A, Lafortune L, Brayne C, Matthews FE Variation over time in the association between polypharmacy and mortality in the older population. Drugs Aging Jul 1 2011, 28:547-560. [Multicenter Study Research Support, Non-U.S. Gov't].
18. Jorgensen T, Johansson S, Kennerfalk A, Wallander MA, Svardsudd K Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother Sep 2001, 35:1004-1009. [Research Support, Non-U.S. Gov't].
19. Beck AT, Steer RA, Brown GK BDI-Fastscreen for medical patients manual 2000, The Psychological Corporation, San Antonio.
20. Benedict RH, Fishman I, McClellan MM, Bakshi R, Weinstock-Guttman B Validity of the Beck Depression Inventory-Fast Screen in multiple sclerosis. Mult Scler Aug 2003, 9:393-396. [Validation Studies].
21. Whiston SC, Eder K Review of the BDI-FastScreen for medical patients. The seventeenth mental measurements yearbook 2003, Buros Institute of Mental Measurement, Lincoln, NE. B.S. Plake, J.C. Impara, R.A. Spies (Eds.).
22. Fisk JD, Ritvo PG, Ross L, Haase DA, Marrie TJ, Schlech WF Measuring the functional impact of fatigue: initial validation of the fatigue impact scale. Clin Infect Dis Jan 1994, 18:S79-S83. [Comparative Study Research Support, Non-U.S. Gov't].
23. Larson RD Psychometric properties of the modified fatigue impact scale. Int J MS Care Spring 2013, 15:15-20.
24. Roberg BL, Bruce JM, Lovelace CT, Lynch S How patients with multiple sclerosis perceive cognitive slowing. Clin Neuropsychol 2012, 26:1278-1295. [Research Support, Non-U.S. Gov't].
25. Smith G, Della Sala S, Logie RH, Maylor EA Prospective and retrospective memory in normal ageing and dementia: a questionnaire study. Memory Sep 2000, 8:311-321.
26. Crawford JR, Smith G, Maylor EA, Della Sala S, Logie RH The Prospective and Retrospective Memory Questionnaire (PRMQ): normative data and latent structure in a large non-clinical sample. Memory May 2003, 11:261-275. [Research Support, Non-U.S. Gov't].
27. Carlson EB, Putnam FW An update on the dissociative experiences scale. Dissociation 1993, 6:16-27.
28. Jackson N, Doherty J, Coulter S Neuropsychiatric complications of commonly used palliative care drugs. Postgrad Med J Mar 2008, 84:121-126. [quiz 5].
29. Bernstein EM, Putnam FW Development, reliability, and validity of a dissociation scale. J Nerv Ment Dis Dec 1986, 174:727-735.
30. Bruce JM, Bruce AS, Hancock L, Lynch S Self-reported memory problems in multiple sclerosis: influence of psychiatric status and normative dissociative experiences. Arch Clin Neuropsychol Feb 2010, 25:39-48. [Research Support, Non-U.S. Gov't].
31. Smith A Symbol digit modalities test 1982, Los Angeles, Western Psychological Services.
32. Drake AS, Weinstock-Guttman B, Morrow SA, Hojnacki D, Munschauer FE, Benedict RH Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. Mult Scler Feb 2010, 16:228-237.
33. Fischer JS, Rudick RA, Cutter GR, Reingold SC The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler Aug 1999, 5:244-250.
34. Lezak M Neuropsychological assessment 1995, Oxford University Press, New York. 3rd ed.
35. Lafosse JM, Mitchell SM, Corboy JR, Filley CM The nature of verbal memory impairment in multiple sclerosis: a list-learning and meta-analytic study. J Int Neuropsychol Soc Oct 2013, 19:995-1008. [Research Support, Non-U.S. Gov't].
36. DeLuca J, Gaudino EA, Diamond BJ, Christodoulou C, Engel RA Acquisition and storage deficits in multiple sclerosis. J Clin Exp Neuropsychol Jun 1998, 20:376-390. [Clinical Trial Research Support, Non-U.S. Gov't].
37. Denney DR, Sworowski LA, Lynch SG Cognitive impairment in three subtypes of multiple sclerosis. Arch Clin Neuropsychol Dec 2005, 20:967-981.
38. Denney DR, Lynch SG, Parmenter BA, Horne N Cognitive impairment in relapsing and primary progressive multiple sclerosis: mostly a matter of speed. J Int Neuropsychol Soc Nov 2004, 10:948-956. [Comparative Study Research Support, Non-U.S. Gov't].
39. Lynch SG, Dickerson KJ, Denney DR Evaluating processing speed in multiple sclerosis: a comparison of two rapid serial processing measures. Clin Neuropsychol Aug 2010, 24:963-976. [Comparative Study Research Support, Non-U.S. Gov't].
40. Woods SP, Moran LM, Dawson MS, Carey CL, Grant I, Group HIVNRC Psychometric characteristics of the memory for intentions screening test. Clin Neuropsychol Sep 2008, 22:864-878. [Clinical Trial Research Support, N.I.H., Extramural].
41. Raskin SA Memory for intentions screening test: psychometric properties and clinical evidence. Brain Impair 2009, 10:23-33.
42. Dennison L, Moss-Morris R Cognitive-behavioral therapy: what benefits can it offer people with multiple sclerosis?. Expert Rev Neurother Sep 2010, 10:1383-1390.
43. Schwartz CE, Kozora E, Zeng Q Towards patient collaboration in cognitive assessment: specificity, sensitivity, and incremental validity of self-report. Ann Behav Med Sep 1996, 18:177-184.
44. Rendell PG, Jensen F, Henry JD Prospective memory in multiple sclerosis. J Int Neuropsychol Soc May 2007, 13:410-416.
45. Umeda S, Kurosaki Y, Terasawa Y, Kato M, Miyahara Y Deficits in prospective memory following damage to the prefrontal cortex. Neuropsychologia Jul 2011, 49:2178-2184.
46. Benoit RG, Gilbert SJ, Frith CD, Burgess PW Rostral prefrontal cortex and the focus of attention in prospective memory. Cereb Cortex Aug 2012, 22:1876-1886.
47. Kojima G, Bell C, Tamura B, Inaba M, Lubimir K, Blanchette PL, et al. Reducing cost by reducing polypharmacy: the polypharmacy outcomes project. J Am Med Dir Assoc Nov 2012, 13. [818 e11-5].